HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in 55 Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) with Extramedullary Disease (EMD)-Subgroup AnalysisPaul G. Richardson, Joan Bladé Creixenti, Johan Harmenberg et al.|Blood|2020Cited by 11
HORIZON (OP-106): Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma with High-Risk Cytogenetics-Subgroup AnalysisMaría‐Victoria Mateos, Paul G. Richardson, Albert Oriol et al.|Blood|2020Cited by 6
HORIZON (OP-106) Versus MAMMOTH: An Indirect Comparison of Efficacy Outcomes for Patients with Relapsed/Refractory Multiple Myeloma Refractory (RRMM) to Anti-CD38 Monoclonal Antibody Therapy Treated with Melflufen Plus Dexamethasone Versus Conventional AgentsJoan Bladé Creixenti, Paul G. Richardson, María‐Victoria Mateos et al.|Blood|2020Cited by 5
HORIZON (OP-106): Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma-Age Subgroup Analysis of Elderly PatientsAlessandra Larocca, María‐Victoria Mateos, Paul G. Richardson et al.|Blood|2020Cited by 3
HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) Exposed to Prior Alkylator Therapy-Subgroup AnalysisPaula Rodríguez‐Otero, Paul G. Richardson, María‐Victoria Mateos et al.|Blood|2020Cited by 2